Drug ID:Drug21
Drug Name:Lidocaine
CID:3676
DrugBank ID:DB00281
Modality:Small Molecule
Groups:approved
US Approved:YES
Other Approved:YES
Identifier: NCT00982618, , NCT01155440
Molecular Formula:C14H22N2O
Molecular Weight:234.34 g/mol
Isomeric SMILES:CCN(CC)CC(=O)NC1=C(C=CC=C1C)C
Synonyms:lidocaine; 137-58-6; Lignocaine; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; Duncaine; Esracaine; Xylestesin; Alphacaine; Cappicaine; Gravocain
Phase 0: 63
Phase 1: 136
Phase 2: 294
Phase 3: 302
Phase 4: 557
Description:A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem]

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt189 3676 Lidocaine 6328 SCN3A Homo sapiens (human) Blocker
dt190 3676 Lidocaine 11280 SCN11A Homo sapiens (human) 37713619 Blocker
dt191 3676 Lidocaine 6336 SCN10A Homo sapiens (human) Inhibitor
dt192 3676 Lidocaine 6335 SCN9A Homo sapiens (human) Inhibitor
dt193 3676 Lidocaine 6331 SCN5A Homo sapiens (human) Inhibitor
dt194 3676 Lidocaine 1956 EGFR Homo sapiens (human) 16551906 Antagonist
dt195 3676 Lidocaine 6329 SCN4A Homo sapiens (human) 14662728 None
dt196 3676 Lidocaine 5004 ORM1 Homo sapiens (human) 8946472 None
dt197 3676 Lidocaine 5005 ORM2 Homo sapiens (human) 8946472 None
dt198 3676 Lidocaine 1576 CYP3A4 Homo sapiens (human) Substrate

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT00982618 Functional Restoration After Abdominal and Pelvic Laparoscopic Surgery: Effect of Perioperative Intravenous Lidocaine None COMPLETED McGill University Health Centre/Research Institute of the McGill University Health Centre Colon Cancer; Inflammatory Bowel Diseases; Divert… DRUG: Lidocaine; PROCEDURE: Epidural Block; DRUG:… Details
NCT01155440 Bowel Function After Laparoscopic Colon Surgery: Effect of IV Lidocaine PHASE2 COMPLETED McGill University Health Centre/Research Institute of the McGill University Health Centre Colon Cancer; Inflammatory Bowel Diseases; Divert… DRUG: Lidocaine; PROCEDURE: Thoracic epidural blo… Details
CTIS2023-508224-35-01 Analgesic effect of intravenous lidocaine and its mechanisms in patients suffering from chronic inflammatory bowel disease (IBD) with abdominal pain. PHASE2 Recruiting CHU De Liege Inflammatory Bowel disease;Therapeutic area: Dise… Product Name: Linisol 1 %, solution injectable, P… Details
ACTRN12616000478415 Intravenous (IV) lidocaine infusions for 48 hours in open colorectal surgery: a prospective, randomised, double-blinded, placebo-controlled trial. PHASE4 Not Recruiting St Vincent's Hospital Sydney Department of Anaesthesia bowel cancer;inflammatory bowel disease;colorecta… Patients undergoing elective open colorectal surg… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Adenosine, lidocaine, and magnesium for attenuating ischemia reperfusion injury…

PMID: 34840271
Year: 2022
Relationship Type: Treatment Score: 6.5

BACKGROUND: Minimally invasive resuscitative endovascular balloon occlusion of the aorta (REBOA) following noncompressible hemorrhage results in sign…

View Details